Connect with us

Technology

PictorLabs and Hamamatsu Photonics announce strategic partnership to explore virtual staining technology

Published

on

BRIDGEWATER, N.J., Oct. 3, 2024 /PRNewswire/ — PictorLabs, a leader in AI-powered virtual staining technology, and Hamamatsu Photonics, a renowned provider of whole slide imaging systems, are excited to announce a strategic partnership to develop cutting-edge applications to advance virtual staining in routine laboratory practices.

Innovations with AI and advanced imaging

PictorLabs, a rapidly growing startup spun off from the UCLA Colleges of Engineering and Medicine, has been at the forefront of the digital transformation of histopathology. By leveraging AI-powered algorithms, PictorLabs eliminates the need for toxic reagents while significantly reducing turnaround times when compared to traditional chemical stain results. With PictorLabs technology and the ability to run multiple stains on a single slide, clinicians and researchers will be able to access digitally stained slides in minutes, enabling faster experiments, less tissue consumption, and better-informed insights.

Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. Known for its NanoZoomer series of whole slide scanners, Hamamatsu has been a pivotal player in advancing digital pathology. NanoZoomer systems are renowned for their reproducibility and reliability, making them a trusted choice for laboratories worldwide.

The collaboration between PictorLabs and Hamamatsu Photonics aims to explore the growing demand for efficient, scalable digital pathology solutions that can ultimately streamline the workflows and accelerate the adoption of digital pathology at an enterprise scale.

Quotes

“This partnership marks a significant milestone in the digital transformation of pathology,” said Yair Rivenson, CEO, CTO & Co-Founder of PictorLabs. “By combining our AI-powered virtual staining technology with Hamamatsu’s state-of-the-art imaging systems, we are poised to revolutionize the way laboratories approach histopathology.”

“As we look into the future of pathology, we aim to explore areas that not only hold potential but also showcase the innovative spirit of Hamamatsu. We are excited to explore these possibilities with Pictor Labs,” said Earl Hergert, President/CEO at Hamamatsu Corporation.

About Hamamatsu Corporation
Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. These devices include photodiodes, silicon photomultipliers, photomultiplier tubes, scientific light sources, infrared detectors, image sensors, spectrometers, cameras, and whole slide imaging systems. The parent company is dedicated to the advancement of photonics through extensive research. This corporate philosophy results in state-of-the-art products which are used throughout the world in scientific, industrial, and commercial applications. For more information, visit www.hamamatsu.com.

About Pictor Labs

PictorLabs is a software company that is transforming the practice of histopathology with AI-powered virtual staining. Based in Los Angeles and spun off from the UCLA Colleges of Engineering and Medicine, PictorLabs is a venture-backed startup leading the digital transformation of histological staining. By delivering digitally stained slides in minutes, PictorLabs will enable faster results with better insights for research, pharma, and clinical applications, ultimately improving histopathology operations and outcomes. For more information about PictorLabs and its AI-powered virtual staining technology, please visit www.pictorlabs.ai.

Information furnished by Hamamatsu Corporation is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions. Specifications are subject to change without notice.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pictorlabs-and-hamamatsu-photonics-announce-strategic-partnership-to-explore-virtual-staining-technology-302266959.html

SOURCE Hamamatsu Corporation

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

New Year, New Health Insurance Changes: BuzzRx® Can Help Fill the Gap in Prescription Coverage

Published

on

By

Save Smart and Bee Healthy

FORT LAUDERDALE, Fla., Jan. 14, 2025 /PRNewswire/ — As we enter a new year, many Americans may be facing unwelcome changes to their health insurance plans, including the removal or reduction of prescription medications from their coverage. With health insurance policies adjusting annually, BuzzRx, a free prescription savings service that allows users to instantly find the lowest price on their medication at pharmacies nationwide, is stepping up to help fill the gap by providing access to affordable prescription medications through exclusive discounts at over 60,000 participating pharmacies nationwide.

The Start of the Year Brings Health Insurance Changes—and Increased Costs

Each year, millions of Americans experience shifts in their health insurance coverage. One of the most common changes is that their prescription medications may no longer be covered. According to the latest data from the Kaiser Family Foundation, nearly 1 in 5 (approximately 23%) individuals with private health insurance face interruptions in their prescription drug coverage once their new policy takes effect. These changes can result in out-of-pocket expenses that are financially burdensome and potentially harmful to individuals’ health.

“Health insurance companies often update their formularies, dropping certain medications or shifting drugs to higher tiers that are not covered as fully,” states Matthew Herfield, Co-Founder and CEO of BuzzRx. “For those who depend on regular medications, these changes can pose a significant financial hardship. BuzzRx is here to help ease that burden by offering discounted prices on prescriptions, regardless of whether your medication is covered by insurance.”

How BuzzRx Can Help You Save on Prescription Medications

BuzzRx offers an affordable and easy way to get the medications you need, even if your insurance no longer covers them. With BuzzRx, users can access exclusive discounts at over 60,000 pharmacies nationwide, including major chains and independent pharmacies.

No insurance? No problem: BuzzRx provides savings on medications for those without insurance or those whose insurance doesn’t cover certain medications.Instant Savings: BuzzRx can save you up to 80% off on prescriptions immediately. Simply show your BuzzRx coupon for your medication at the pharmacy to receive your discount.Broad Coverage: BuzzRx offers discounts on a wide range of medications, including generic and brand-name drugs.Simple & Free: Signing up for BuzzRx is quick and free—no hidden fees, no complicated paperwork, and no waiting periods.

In addition, BuzzRx’s BeeKind program gives back to four nonprofit partners every time someone saves, ensuring that every discount used can help others in need.

The Impact of Losing Prescription Coverage

Losing coverage for critical medications can have far-reaching consequences. According to a study by the National Public Radio (NPR), as many as 33% of Americans report not filling prescriptions due to high out-of-pocket costs. When health insurance no longer covers necessary medications, many are forced to make difficult choices between buying medications or paying for other essential needs.

It’s easy to start saving with BuzzRx. Simply visit buzzrx.com or download the BuzzRx app to sign up for a free BuzzRx account and begin accessing prescription discounts immediately.

About BuzzRx
BuzzRx is a free prescription discount service that allows users to find the lowest price on their medication instantly at over 60,000 pharmacies nationwide. The website and free mobile app promote drug transparency by allowing users to compare discounted prices across pharmacy chains, helping reduce out-of-pocket costs and sticker shock at the counter. Since 2021, BuzzRx has helped over 10 million people in the U.S. save up to 80% on their medications, resulting in over $2 billion saved. BuzzRx also supports its nonprofit partners year-round, donating over 10 million. For more information, visit BuzzRx.com or download the free mobile app on iOS and Android.

Press Contact
Press@BuzzRx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-year-new-health-insurance-changes-buzzrx-can-help-fill-the-gap-in-prescription-coverage-302349788.html

SOURCE BuzzRx

Continue Reading

Technology

USTA President Brian Hainline, MD Joins Tennis Social AI as Chief Innovation & Health Officer

Published

on

By

NEW YORK, Jan. 14, 2025 /PRNewswire/ — Tennis Social AI proudly announces Brian Hainline, MD as its Chief Innovation and Health Officer, marking a transformative step in its mission to redefine tennis and racquet sports.

“Tennis Social AI addresses a critical gap in bringing tennis to the people.” – Brian Hainline, MD

Brian, former President of the USTA and the first Chief Medical Officer of the NCAA, brings decades of leadership and expertise at the intersection of health, sports, and innovation. A Clinical Professor of Neurology at NYU Grossman School of Medicine, Brian has been a vocal advocate for tennis as the healthiest sport in the world. His role at Tennis Social AI will focus on driving cutting-edge initiatives to broaden the sport’s accessibility, unlock its health benefits, and integrate technology to elevate the player experience.

“Tennis is the healthiest sport on the planet – but that only matters if tennis is accessible to individuals and communities from all cultures, all ages, and all abilities,” Brian shared. “Tennis Social AI addresses a critical gap in bringing tennis to the people – tennis that is fun, engaging, and a platform for developmental success. I feel privileged to be part of this journey.”

At Tennis Social AI, the mission is to make tennis more social, fun, and accessible to everyone, regardless of age, ability, or skill level. Brian’s addition to the team comes as the company prepares for its first installations and public launch in early 2025.

Rooted in tennis, Tennis Social AI’s proprietary technology also holds the potential to revolutionize other racquet sports, including pickleball and padel. This versatility positions the company as a leader in racquet sports simulation.

2025 promises to redefine racquet sports innovation. Tennis Social AI will blend entertainment, fitness, and training, paving the way for a future where the sport inspires and stays accessible to all.

For more information on brand opportunities and pre-sales, contact: Steven McClendon at steven@tennissocial.ai / Tyler Kelly at Tyler@tennissocial.ai or visit https://tennissocial.ai/

View original content:https://www.prnewswire.com/news-releases/usta-president-brian-hainline-md-joins-tennis-social-ai-as-chief-innovation–health-officer-302349458.html

SOURCE Tennis Social AI

Continue Reading

Technology

Tyber Medical, Intech and Resolve Surgical Technologies combine to form a next-generation solutions provider to the Medical Device industry

Published

on

By

LONDON, Jan. 14, 2025 /PRNewswire/ — Montagu announced today its intention to create a world-leading medical devices supplier by supporting the merger of Tyber Medical, Intech and Resolve Surgical Technologies (“Resolve”).

As part of the transaction, Montagu entered into a definitive agreement to acquire Tyber Medical, an innovative medical device company providing private label development and manufacturing services to med-tech Original Equipment Manufacturers (OEMs). Subject to customary regulatory approvals and closing conditions, Tyber Medical will be combined with Montagu’s existing investments in Resolve, a leading provider of contract device design, manufacturing, and lifecycle management services, as well as in Intech, a leader in the co-development and manufacturing of complex orthopaedic surgical devices.

The combined entity will offer a unique mix of proprietary market-cleared technologies, and development and manufacturing scale, that will enable its OEM customers to achieve unmatched speed to market and improve the resiliency and effectiveness of their supply chain. At the time of the merger, the platform will be a leading contract supplier of systems for Spine, Trauma, Extremities, Sports Medicine and Enabling Technologies, with plans to expand its pioneering innovation-led model into additional markets. The planned merger will support accelerated innovation and help improve standards of care for patients globally.

Jeff Tyber, Founder and CEO at Tyber Medical said: “Tyber Medical’s proven track record of successful global launches, averaging 12 months from signing to launch, has revolutionized how our partners expand their portfolios and adapt to the evolving market dynamics. This strategic combination brings together the size, scale, and expertise of Intech, along with Resolve’s deep knowledge in the Spine and Cardiothoracic fields. We are delighted to be partnering with Montagu, a leading investment firm in the private label OEM sector, and we share their vision of creating an industry champion.”

“This unique combination represents a significant milestone, enhancing our ability to serve medical technology companies worldwide,” said Laurent Pruvost, President and CEO of Intech. “By combining Intech’s global manufacturing footprint and know-how with Resolve and Tyber’s tailored solutions, we will establish ourselves as the undisputed partner of choice in the industry.”

Megan Osorio, President and CEO of Resolve said: “Bringing innovation to market with speed and quality is of the utmost importance to our OEM customers. Joining forces will increase our ability to support their growth across the full range of orthopaedic implants & instruments by bringing the deep experience of our respective teams and scale of our manufacturing footprint together.”

Adrien Sassi, Partner at Montagu said: “Montagu is proud to support the creation of this world-class medical device platform. The three organisations share similar passion and focus on delivering innovative, high-quality, reliable solutions to OEM customers, surgeons, and patients. We look forward to partnering with Jeff Tyber and his talented team, as well as extending our successful collaboration with Intech and Resolve.”

Houlihan Lokey and Dechert LLP, respectively, acted as exclusive financial advisor and legal advisor to Tyber Medical. Weil Gotshal & Manges acted as legal advisor to Montagu, Intech and Resolve.

Media enquiries

Greenbrook: James Madsen and Cecilie Oerting
+44 20 7952 2000 | montagu@greenbrookadvisory.com

About Intech

Intech is a global leader in the manufacturing of orthopaedic devices and mission-critical components. With facilities in the USA, Europe, and Asia-Pacific, the group excels in producing surgical implants, instruments, cutting tools, handles, and sterilization containers. With innovation at heart, Intech is at the forefront of contract-design and contract-manufacturing in the field of Orthopaedics and Healthcare. Intech is also home to SMADE, its IoMT division that offers smart tracking of geolocation, sterilisation cycles, and usage of surgical containers on the field. For more information, visit https://intech-medical.com/.

About Resolve Surgical Technologies

Resolve Surgical Technologies is an industry-leading private label OEM that designs, develops and manufactures metal and polymer implants and instruments serving the orthopaedics, spine and cardiothoracic markets. Originally founded in 1992 as Pioneer Surgical Technology, Inc. and later known as the Metals division of RTI Surgical, Resolve became known for their innovative designs and engineering expertise. Today, Resolve Surgical focuses on creating value as an extension of our OEM partners’ teams to deliver innovation, accelerate speed to revenue and drive lifecycle management with robust quality and regulatory support. For more information, visit www.resolvesurg.com.

About Tyber Medical LLC

Tyber Medical LLC is a leading orthopaedic device manufacturer providing rapid access to FDA-cleared and CE-marked, private label, portfolio-enhancing regulatory-approved orthopaedic implants for the spinal, extremity, and trauma markets. Since its founding in 2012, the company has released more than 50 spine, extremity, and trauma systems. Tyber Medical aims to develop and utilize differentiated bioengineered technologies, including surface treatments and coatings, to advance orthopaedic science. For more information, visit https://tybermedical.com/.

About Montagu

Montagu is a leading mid-market private equity firm, committed to finding and growing businesses that make the world work. Focussing on businesses with a must-have product or service in a structurally growing marketplace, Montagu brings proven growth capabilities to help companies achieve their ambitions and unlock their full potential. Montagu specialises in carve-out and other first time buyout investments and has deep expertise in five priority sectors: Healthcare, Financial Sector Services, Critical Data, Digital Infrastructure and Education. ESG forms an integral part of its strategy, and its commitment to responsible investment is fully integrated into its investment and value-creation process. Montagu partners with companies with enterprise values between €200 million and €1 billion and has €12bn assets under management. For additional information on Montagu, visit www.montagu.com

 

 

View original content:https://www.prnewswire.co.uk/news-releases/tyber-medical-intech-and-resolve-surgical-technologies-combine-to-form-a-next-generation-solutions-provider-to-the-medical-device-industry-302350537.html

Continue Reading

Trending